AKIMASA ICHINOE    Department   School of Medicine(Tokyo Women's Medical University Adachi Medical Center), School of Medicine    Position   Assistant Professor
Article types	Original article
Language	English
Peer review	Peer reviewed
Title	Retrospective Analysis of Concurrent Chemoradiation with Triweekly Cisplatin plus 5-Fluorouracil Versus Weekly Cisplatin in Cervical Cancer.
Journal	Formal name：Anticancer research Abbreviation：Anticancer Res ISSN code：02507005/17917530
Volume, Issue, Page	35(6),pp.3447-3454
Author and coauthor	KENZO SONODA†, HIDEAKI YAHATA, AKIMASA ICHINOE, KAORU OKUGAWA, EISUKE KANEKI, YOSHIAKI KAWANO, HIRONORI KENJO, TATSUHIRO OHGAMI, HIROSHI YAGI, SAIJI OHGA, KAORI ASAI, KATSUMASA NAKAMURA, HIROSHI HONDA, KIYOKO KATO*
Publication date	2015
Summary	Background/Aim: Concurrent chemoradiation (CCRT) is the standard treatment for locally advanced cervical cancer. The purpose of the study was to compare the outcomes of triweekly cisplatin plus 5-fluorouracil and weekly cisplatin regimens. Patients and Methods: We retrospectively reviewed data from 91 patients with stage IB1-IVA cervical cancer. Results: Out of 91 patients, 48 received triweekly CCRT and 43 received weekly CCRT. For triweekly CCRT, patients received a median of two chemotherapy cycles and median total doses of cisplatin and 5-fluorouracil were 210 mg/body and 8,525 mg/body, respectively. For weekly CCRT, patients received a median of five chemotherapy cycles and the median total dose of cisplatin was 252 mg/body. No statistically significant differences in overall survival or progression-free survival were noted between the two groups. Conclusion: Both triweekly CCRT and weekly CCRT appear to have similar efficacy for cervical cancer patients, but the toxicities were better tolerable in weekly CCRT.